JPRN-jRCT2091220020已完成3 期
Double-Blind Study of IDEC-C2B8 in Patients with Childhood-onset Complicated FRNS or SDNS - RCRNS01
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
We have shown that the relapse-free period increases with rituximab in patients with childhood-onset, complicated FRNS and SDNS. Adverse events were generally mild and the frequency of serious adverse events did not differ significantly between groups. Rituximab is an effective and safe treatment for childhood-onset, complicated FRNS and SDNS.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 2age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Diagnosed as idiopathic nephrotic syndrome (INS) according to the ISKDC criteria.
- •2. Subjects meeting either one of the following criteria:
- •1) Diagnosed as frequently relapsing or steroid-dependent INS again after immunosuppressant treatment such as cyclosporine A, cyclophosphamide and/or mizoribine for previous frequently relapsing or steroid-dependent NS.
- •2) Diagnosed as frequently relapsing or steroid-dependent INS during immunosuppressant treatment such as cyclosporine A, cyclophosphamide and/or mizoribine for previous frequently relapsing or steroid-dependent NS.
- •3) Diagnosed as frequently relapsing or steroid-dependent INS after or during treatment with cyclosporine A alone or in combination with methylprednisolone for previous steroid-resistant NS which was initially diagnosed as NS.
- •3. First onset of INS is between 1 - 18 years of age, and 2 years of age or older at entry.
- •4. Subjects with records of nearest preceding 3 relapses
- •5. Diagnosed as steroid-sensitive relapse
- •6.CD20 positive B-cells >/= 5/mcL in the peripheral blood
- •7. Subjects can be hospitalized for treatments
- •8. Subjects have ability to provide written informed consent form. The written informed consent form of legal representative (i.e., a parent or a legal benefactor) is also required for subjects less than 20 years of age.
排除标准
- •1. History of inflammatory nephritis such as IgA nephritis.
- •2. History of immunosuppressive treatment for INS other than cyclosporine A, cyclophosphamide, mizoribine, mycophenolate mofetil and chlorambucil
- •3. History of serious infectious diseases such as pulmonary tuberculosis and deep-seated fungal diseases
- •4. Positive for HCV antibody, HBs antigen, HBc antibody and HIV antibody
- •5. Having received a live vaccine within 4 weeks prior to screening
- •6.Known hypertension which is uncontrollable with conventional anti-hypertensive
- •7. Deteriorated kidney function, e.g. estimated GFR<60mL/min./1.73m2
- •8. Deteriorated liver function, e.g., AST or ALT > 2.5 x upper limit of normal value
- •9. Presence or history of angina pectoris, cardiac failure, myocardial infarction and/or serious arrhythmia grade 4 in Common Terminology Criteria for Adverse Events (ver. 3.0)
- •10. Presence or history of auto-immune diseases such as Hashimoto disease (struma lymphomatosa), Crohn's disease, ulcerative colitis, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma or vascular purpura
- •11. Presence or history of cancer
- •12. History of organ transplantation
- •13. History of allergic reaction to acetaminophen and/or d-chlorpheniramine maleate
- •14. Presence of hematological disorder, e.g., WBC < 2,000/mcL, neutrophil < 1,500/mcL, PLT < 50,000/mcL
- •15. History of receiving any kinds of monoclonal antibody therapy
- •16. Having received any investigational agent within 6 months prior to enrollment, or participating other clinical studies
- •17. Pregnant subjects or subjects who do not agree with contraception during the study period (Negative HCG result is required at screening for female subjects after the first menstruation.)
- •18.Judged inappropriate for this study by the physicians
研究者
相似试验
终止
2 期
R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic LymphomaChronic Lymphocytic LeukaemiaSmall Lymphocytic LymphomaNCT01446900European Institute of Oncology25
已完成
不适用
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic PurpuraIdiopathic Thrombocytopenic PurpuraImmune Thrombocytopenic PurpuraNCT01713855Neufeld, Ellis J, MD, PhD10
进行中（未招募）
1 期
Rituximab-induced remission in CIDP (ReCIX study)CTIS2024-512506-25-00Amsterdam UMC Stichting102
已完成
2 期
Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab EvaluationPrimary Mediastinal Large B Cell LymphomaNCT01516567Gustave Roussy, Cancer Campus, Grand Paris47
招募中
3 期
Early rituximab treatment in children with idiopathic nephrotic syndrome Eng. ERICONS - Early RITUXIMAB in Childhood Onset Nephrotic Syndrome2024-515058-26-00Medical University Of Gdansk60